Advertising

CVE:PTQ

2.06
0.11 (5.07%) 1d
0
Showing 1 to 14 of 14 entries
  • «
  • 1
  • »
PAST TOP PICK
(A Top Pick May 29/20, Up 55%) Oxygen delivery. Recurring revenue model. Very strong outlook.
biotechnology / pharmaceutical
PAST TOP PICK
(A Top Pick May 27/20, Up 65%) They plan on changing their name and moving onto the Nasdaq. They fly under the radar but trade at an attractive valuation. He's sticking with this. It will continue to do well on the Nasdaq.
biotechnology / pharmaceutical
BUY
US focused. Lifts, supports, oxygen services. They've been acquirers. Brought debt down, increased profit margin, grown geographically. Still very attractively valued compared to its peers. Could be a takeover target.
biotechnology / pharmaceutical
BUY
A US company that's consolidating in the medical market (home lifts, ventilators, oxygen, etc.). He continues to like it. It was a past pick and since they made an acquisition. The stock has increased, though not as much as he expected. He predicts the valuation will be pretty attractive. This could be a takeover target and it's firing on all cylinders.
biotechnology / pharmaceutical
TOP PICK
It continues to stay in this valuation range. They are in the home medical business. They operate in ten states and have 40 locations. It is a fragmented industry. They have 68% recurring revenue. They have a huge opportunity to consolidate. They can grow through valuation multiple growth and organically. (Analysts’ price target is $2.36)
biotechnology / pharmaceutical
TOP PICK
A perfect stock even though it is up 50% off the lows. They can service the debt and earnings expected to grow by 133%. Yield 0% (Analysts’ price target is $2.36)
biotechnology / pharmaceutical
TOP PICK
They are taking advantage of in-home health care during the pandemic. It trades at about a third of their peers, yet growth has been 20% per year. They focus on an area of the medical space that will get head winds from COVID. It will likely be taken out sometime later this year. Yield 0% (Analysts’ price target is $2.36)
biotechnology / pharmaceutical
BUY
This is one that a piece of their business benefits from COVID. Oxygen sales, sleep apnea, as people get released FROM COVID hospitalization, they can get onto home ventilators. He likes it. It was a past top pick.
biotechnology / pharmaceutical
PAST TOP PICK

(A Top Pick Jan 30/19, Down 4%) He would have expected it to do more. He is quite confident going forward. He thinks they will get taken out within 18 months. Almost made it a top pick again.

biotechnology / pharmaceutical
DON'T BUY

They had a cyber theft – 9 Million out of there bank but insurance covered it. He likes it. It is speculative and is a roll up strategy.

biotechnology / pharmaceutical
PAST TOP PICK
(A Top Pick Dec 12/18, Up 41%) It continues to grow organically and by acquisition. It is very attractive at less than 8 times earnings, which are growing at 12-15% per year. It will either get recognized by the market or get taken out.
biotechnology / pharmaceutical
BUY

They've recently announced they had a cyber attack and lost $9 million but they should get most of it back. They'll be then able to go do more mergers and acquisitions after, which should be in September. The valuation is very attractive, and it should bounce up when they make the press release that they have recovered their funds.

biotechnology / pharmaceutical
BUY
In the U.S. healthcare business. They have transformed in the past year, raising profit margins and accounts receivable. They are highly profitable around 20%. Trades at less than 10x 2020's EBITDA. Management continues to execute, doing small acqusitions.
biotechnology / pharmaceutical
TOP PICK
They just released earnings this week and they have been turning their business around -- increasing margins and growing organically. Management owns about 18% of the shares and it trades at 5 times earnings. He thinks it could trade at twice that level. They are involved in patient home monitoring. Yield 0% (Analysts’ price target is $3.00)
biotechnology / pharmaceutical
Showing 1 to 14 of 14 entries
  • «
  • 1
  • »

Protech Home Medical Corp(PTQ-X) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 3

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 3

Stockchase rating for Protech Home Medical Corp is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Protech Home Medical Corp(PTQ-X) Frequently Asked Questions

What is Protech Home Medical Corp stock symbol?

Protech Home Medical Corp is a Canadian stock, trading under the symbol PTQ-X on the TSX Venture Exchange (PTQ-CV). It is usually referred to as TSXV:PTQ or PTQ-X

Is Protech Home Medical Corp a buy or a sell?

In the last year, 3 stock analysts published opinions about PTQ-X. 3 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Protech Home Medical Corp.

Is Protech Home Medical Corp a good investment or a top pick?

Protech Home Medical Corp was recommended as a Top Pick by on . Read the latest stock experts ratings for Protech Home Medical Corp.

Why is Protech Home Medical Corp stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Protech Home Medical Corp worth watching?

3 stock analysts on Stockchase covered Protech Home Medical Corp In the last year. It is a trending stock that is worth watching.

What is Protech Home Medical Corp stock price?

On 2021-05-12, Protech Home Medical Corp (PTQ-X) stock closed at a price of $2.06.